Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44064   clinical trials with a EudraCT protocol, of which   7320   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-003149-41
    Sponsor's Protocol Code Number:IgPro20_2001
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2019-03-27
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2018-003149-41
    A.3Full title of the trial
    A Multicenter, Randomized, Open-label, Crossover, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of IgPro20 (subcutaneous immunoglobulin, Hizentra®) and IgPro10 (intravenous immunoglobulin, Privigen®) in Adults with Systemic Sclerosis (SSc).
    Étude de phase II multicentrique, randomisée, menée en ouvert, avec permutation des traitements, visant à évaluer la sécurité d’emploi et la pharmacocinétique de l’IgPro20 (immunoglobuline injectable par voie sous-cutanée, Hizentra®) et de l’IgPro10 (immunoglobuline injectable par voie intraveineuse, Privigen®) chez des patients adultes atteints de sclérodermie systémique (ScS).
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults with Systemic Sclerosis (SSc).
    La sécurité d’emploi et la pharmacocinétique de l’IgPro20 et de l’IgPro10 chez des patients adultes atteints de sclérodermie systémique (ScS).
    A.3.2Name or abbreviated title of the trial where available
    n/a
    A.4.1Sponsor's protocol code numberIgPro20_2001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCSL Behring GmbH
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportCSL Behring GmbH
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationCSLB
    B.5.2Functional name of contact pointTrial Registration Coordinator
    B.5.3 Address:
    B.5.3.1Street Address1020 First Ave,
    B.5.3.2Town/ cityKing of Prussia,PA
    B.5.3.3Post code19406
    B.5.3.4CountryUnited States
    B.5.4Telephone number0016108784000
    B.5.6E-mailclinicaltrials@cslbehring.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Hizentra
    D.2.1.1.2Name of the Marketing Authorisation holderCSL Behring GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameHuman normal immunoglobulin for subcutaneous administration
    D.3.2Product code IgPro20
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHuman normal immunoglobulin
    D.3.9.2Current sponsor codeIgPro20
    D.3.9.3Other descriptive nameHUMAN NORMAL IMMUNOGLOBULIN
    D.3.9.4EV Substance CodeSUB14196MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product Yes
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Privigen
    D.2.1.1.2Name of the Marketing Authorisation holderCSL Behring GmbH
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameHuman normal immunoglobulin for intravenous administration
    D.3.2Product code IgPro10
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNHuman normal immunoglobulin
    D.3.9.2Current sponsor codeIgPro10
    D.3.9.3Other descriptive nameHUMAN NORMAL IMMUNOGLOBULIN
    D.3.9.4EV Substance CodeSUB14196MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) Yes
    D.3.11.7Plasma derived medicinal product Yes
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Safety and Pharmacokinetics in subjects with diffuse cutaneous systemic sclerosis
    E.1.1.1Medical condition in easily understood language
    Scleroderma (systemic sclerosis)
    Sclérodermie systémique
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10012977
    E.1.2Term Diffuse systemic sclerosis
    E.1.2System Organ Class 100000004859
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the study is to evaluate the safety of IgPro20 in adults with dcSSc.
    L’objectif principal de l’étude est d’évaluer l’innocuité de l’IgPro20 chez des adultes atteints de ScScd.
    E.2.2Secondary objectives of the trial
    The secondary objectives of the study are to evaluate:
    • Relative bioavailability of IgPro20
    • Pharmacokinetics of IgPro20
    • Pharmacokinetics of IgPro10
    • Safety of IgPro10
    Les objectifs secondaires de l’étude sont d’évaluer :
    • La biodisponibilité relative de l’IgPro20
    • La PK de l’IgPro20
    • La PK de l’IgPro10
    • L’innocuité de l’IgPro10
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Age ≥ 18 years (male or female) at time of providing written informed consent
    2. Documented diagnosis of systemic sclerosis (scleroderma) according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) criteria 2013 (diffuse cutaneous form of SSc).
    3. mRSS ≥ 15 and ≤ 45 at screening
    4. Disease duration ≤ 5 years defined as the time from the first non-Raynaud’s phenomenon manifestation
    5. A female who is not pregnant, not breastfeeding, and either is not a woman of childbearing potential or is a woman of childbearing potential who agrees to use acceptable methods of contraception
    6. Capable of providing written informed consent and willing and able to adhere to all protocol requirements
    1. (Homme ou femme) ≥ 18 ans au moment de la fourniture du consentement éclairé écrit
    2. Diagnostic de sclérodermie systémique documenté selon les critères 2013 de l’American College of Rheumatology et de l’European League Against Rheumatism (forme cutanée diffuse de la ScS).
    3. Score cutané de Rodnan modifié (mRSS) ≥ 15 et ≤ 45 à la sélection
    4. Durée de la maladie ≤ 5 ans, définie comme le temps depuis la première manifestation d’un phénomène non-Raynaud
    5. La femme qui n'est pas enceinte, qui n'allaite pas, qui, soit n'est pas une femme en âge de procréer, soit est une femme en âge de procréer qui accepte d'utiliser des méthodes de contraception acceptables
    6. Le patient est capable de fournir un consentement éclairé écrit, il est prêt à adhérer à toutes les exigences du protocole, et est en mesure de le faire
    E.4Principal exclusion criteria
    1. Primary rheumatic autoimmune disease other than dcSSc, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disorder, polymyositis, dermatomyositis, as determined by the investigator. Note: Subjects with fibromyalgia, secondary Sjogren’s syndrome, and scleroderma-associated myopathy at screening are not excluded
    2. Subject has mRSS > 2 at the potential subcutaneous (SC) infusion sites
    3. History of skin condition precluding SC infusion, or clinical signs and symptoms of a chronic skin disease other than systemic sclerosis or skin manifestation of an allergic disease or other dermatological conditions that would interfere with trial assessments or compromise safety (eg, dermatitis, eczema, psoriasis)
    4. Subject has clinical sign and symptoms of skin irritation (eg, pruritus, burning, erythema) or hypo/ hyperpigmentations (eg, scars, tattoos) at the potential SC infusion sites
    5. Significant pulmonary arterial hypertension (PAH) as documented by mean pulmonary arterial pressure (PAP) > 30 mmHg on right heart catheterization requiring SC or IV prostacyclin or use of dual oral therapies
    6. FVC < 50% predicted or a diffusing capacity of the lung for carbon dioxide (DLCO) ≤ 40% predicted (corrected for hemoglobin) at screening

    1. Maladie rhumatismale auto-immune primaire autre qu’une ScScd, dont, entre autres, polyarthrite rhumatoïde, lupus érythémateux systémique, maladie mixte du tissu conjonctif, polymyosite, dermatomyosite, telle que déterminée par l’investigateur. Remarque : les sujets atteints à la sélection de fibromyalgie, de Syndrome de Sjögren secondaire et de myopathie associée à la sclérodermie ne sont pas exclus
    2. Sujet avec un mRSS > 2 aux sites de perfusion SC potentiels
    3. Antécédents de maladie cutanée ou de signes et symptômes cliniques d’une maladie cutanée chronique autre qu’une ScS, ou de manifestation cutanée d’une maladie allergique, ou d’autres pathologies dermatologiques interdisant la perfusion SC au niveau des sites de perfusion SC potentiels
    4. Sujet présentant des signes et symptômes cliniques d’irritation cutanée (par exemple, prurit, brûlure, érythème) ou des hypo/ hyperpigmentations (par exemple, cicatrices, tatouages) aux sites de perfusion SC potentiels
    5. Hypertension artérielle pulmonaire significative telle que documentée par une pression artérielle pulmonaire moyenne > 30 mmHg au cathétérisme cardiaque droit nécessitant de la prostacycline SC ou intraveineuse (IV) ou l’utilisation d’une double thérapie orale
    6. Anticipation d’une CVF < 50 % ou d’une capacité de diffusion pour le monoxyde de carbone (DLCO) ≤ 40 % (corrigée pour l’hémoglobine) à la sélection

    E.5 End points
    E.5.1Primary end point(s)
    - Number and percentage of subjects with adverse events (AEs) for IgPro20
    - Number and percentage of patients with AEs categorized as injection site reactions (ISRs) for IgPro20
    - Rate of ISRs per subject for IgPro20
    - Rate of ISRs per infusion for IgPro10
    - Onset of ISRs for IgPro20
    - Duration of ISRs for IgPro20
    - Nombre et pourcentage de sujets présentant des événements indésirables (EI) pour l’IgPro20
    - Nombre et pourcentage de sujets présentant des EI classés comme réactions au site d’injection (RSI) pour l’IgPro20
    - Taux de RSI par sujet pour l’IgPro20
    - Taux de RSI par perfusion pour l’IgPro10
    - Apparition des RSI pour l’IgPro20
    - Durée des RSI pour l’IgPro20

    E.5.1.1Timepoint(s) of evaluation of this end point
    Up to 16 weeks
    Jusqu’à 16 semaines
    E.5.2Secondary end point(s)
    - IgPro20 relative bioavailability (%F)
    - Area under the concentration curve to the end of the dosing period (AUC0-tau) for IgPro20
    - Area under the concentration curve up to the last measurable concentration (AUC0-last) for IgPro20
    - Maximum [peak] plasma drug concentration (Cmax) for IgPro20
    - Minimum plasma drug concentration (Ctrough) for IgPro20
    -Area under the concentration curve to the end of the dosing period (AUC0-tau) for IgPro10
    -Area under the concentration curve up to the last measurable concentration (AUC0-last) for IgPro10
    -Maximum [peak] plasma drug concentration (Cmax) for IgPro10
    -Minimum plasma drug concentration (Ctrough) for IgPro10
    -Number and percentage of subjects with adverse events (AEs) for IgPro10
    -Number and percentage of subjects with AEs categorized as ISRs for IgPro10
    - Biodisponibilité relative (%F) de l’IgPro20
    - Aire sous la courbe de la concentration jusqu’à la fin de la période d’administration (AUC0-tau) pour l’IgPro20
    - Aire sous la courbe de la concentration jusqu’à la dernière concentration mesurable (AUC0-dernière) pour l’IgPro20
    - Concentration plasmatique maximum [pic] du médicament (Cmax) pour l’IgPro20
    - Concentration plasmatique minimum (Cmini) du médicament pour l’IgPro20
    - Aire sous la courbe de la concentration jusqu’à la fin de la période d’administration (AUC0-tau) pour l’IgPro10
    - Aire sous la courbe de la concentration jusqu’à la dernière concentration mesurable (AUC0-dernière) pour l’IgPro10
    - Concentration plasmatique maximum [pic] du médicament (Cmax) pour l’IgPro10
    - Concentration plasmatique minimum (Cmini) du médicament pour l’IgPro10
    - Nombre et pourcentage de patients présentant des événements indésirables (EI) pour l’IgPro10
    - Nombre et pourcentage de patients présentant des EI classés comme réactions au niveau du point d’injection pour l’IgPro10
    E.5.2.1Timepoint(s) of evaluation of this end point
    - Up to 16 weeks
    - Up to 240 hours after first infusion
    - Up to 240 hours after first infusion
    - Up to 240 hours after first infusion
    - Prior to infusion
    - Up to 672 hours after first infusion
    - Up to 672 hours after first infusion
    - Up to 672 hours after first infusion
    - Prior to infusion
    - Up to 16 weeks
    - Up to 16 weeks
    - Jusqu’à 16 semaines
    - Jusqu’à 240 heures après la première perfusion
    - Jusqu’à 240 heures après la première perfusion
    - Jusqu’à 240 heures après la première perfusion
    - Avant perfusion
    - Jusqu’à 672 heures après la première perfusion
    - Jusqu’à 672 heures après la première perfusion
    - Jusqu’à 672 heures après la première perfusion
    - Avant perfusion
    - Jusqu’à 16 semaines
    - Jusqu’à 16 semaines
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy No
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Bio availability
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over Yes
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Two treatment periods: IgPro10 and then IgPro20 or vice versa
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA13
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    France
    Germany
    Italy
    Poland
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the clinical study (ie, completion of the study at all participating study sites) is defined as the date of the last visit of the last subject and consists of a telephone call to assess safety.
    La fin de l’essai clinique (étude achevée dans tous les centres participant à la recherche) est définie comme la date de la dernière visite du dernier patient et prend la forme d’un appel téléphonique pour évaluer l’innocuité.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months24
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months24
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 26
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state2
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 22
    F.4.2.2In the whole clinical trial 26
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-05-24
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-05-07
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2022-05-17
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA